{"schema_version":"secwatch.filing_event.v1","accession":"0001831868-25-000006","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.209766+00:00","generated_at":"2026-05-17T13:59:18.576239+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SeaStar Medical Q2 net loss $2.0M; NEUTRALIZE-AKI trial over 60% enrolled","bullets":["Net revenue $0.3M from QUELIMMUNE sales; net loss $2.0M ($0.18/share) vs $3.2M loss year ago.","NEUTRALIZE-AKI trial enrolled 125 of 200 patients; interim DSMB recommendations expected Q3 2025.","Three new children's hospitals adopted QUELIMMUNE; SAVE registry shows 75% 28-day survival in 20 pediatric patients.","Raised $12.4M in June and $8.4M in two July/August 2025 offerings; cash at June 30 was $6.3M.","CMS agreed to cover clinical trial expenses for NEUTRALIZE-CRS; DoD awarded $2M grant for burn research."],"urls":{"canonical":"https://secwatch.observer/filing/0001831868-25-000006","json":"https://secwatch.observer/filing/0001831868-25-000006.json","markdown":"https://secwatch.observer/filing/0001831868-25-000006.md","text":"https://secwatch.observer/filing/0001831868-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000183186825000006/0001831868-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000183186825000006/icu-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:59:18.576239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}